keyword
MENU ▼
Read by QxMD icon Read
search

Cardiology drugs

keyword
https://www.readbyqxmd.com/read/28533838/-predictive-factors-of-medication-adherence-in-patients-with-chronic-heart-failure-morocco-s-experience
#1
Yassine Ragbaoui, Imad Nouamou, Ayoub El Hammiri, Rachida Habbal
Medication adherence in patients with chronic heart failure is recognized as one of the major issues in the management of this pathology. Demographic status and socioeconomic conditions in African countries may have an impact on chronic heart failure treatment adherence. We conducted a cross-sectional study of patients with heart failure treated in the center of heart failure in the Department of Cardiology at the IBN ROCHD University Hospital (Morocco) from September 2014 to January 2015. The extent of medication adherence was based on a questionary: CARDIA-Questionary...
2017: Pan African Medical Journal
https://www.readbyqxmd.com/read/28528469/multiple-sclerosis-treatment-with-fingolimod-profile-of-non-cardiologic-adverse-events
#2
REVIEW
Yara Dadalti Fragoso
Fingolimod was the first oral medication approved for management of multiple sclerosis and is currently used by tens of thousands patients worldwide. Fingolimod acts via the sphingosine 1-phosphate (S1P) receptor, maintaining peripheral lymphocytes entrapped in the lymph nodes. In consequence, there is a reduction in the infiltration of aggressive lymphocytes into the central nervous system. The drug is safe and effective, and its first hours of use are associated with related to S1P receptors in the heart...
May 20, 2017: Acta Neurologica Belgica
https://www.readbyqxmd.com/read/28526014/the-use-of-lipid-lowering-therapy-and-effects-of-antihyperglycaemic-therapy-on-lipids-in-subjects-with-type-2-diabetes-with-or-without-cardiovascular-disease-a-pooled-analysis-of-data-from-eleven-randomized-trials-with-insulin-glargine-100%C3%A2-u-ml
#3
Markolf Hanefeld, Louise Traylor, Ling Gao, Wolfgang Landgraf
BACKGROUND: Dyslipidaemia is a major contributor to the increased risk of cardiovascular disease (CVD) associated with type 2 diabetes (T2D). This study aimed to characterize the extent of lipid-lowering therapy use and its impact on lipid and glycaemic outcomes in people with T2D uncontrolled on oral agents who were enrolled in insulin glargine 100 units/mL (Gla-100) randomized controlled trials (RCTs). METHODS: A post hoc patient-level pooled analysis of eleven RCTs (≥24 weeks' duration) comparing Gla-100 (±oral antidiabetes drugs [OADs]) with OADs alone in people with T2D was performed...
May 19, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/28504231/poland-coronary-and-structural-heart-interventions-from-2010-to-2015
#4
Jacek Legutko, Zbigniew Siudak, Radosław Parma, Andrzej Ochała, Dariusz Dudek
For the last five years, invasive cardiology in Poland has developed extensively. Currently, 98% of the 161 Polish cathlabs operate in 24/7 mode, 37 of them supported by cardiac surgery departments on-site. A certification curriculum for interventional cardiology operators is supported by dedicated workshops and scientific meetings during national conferences. The rise in the number of coronary angiographies and PCIs was paralleled by an increased use of drug-eluting stents, bioresorbable vascular scaffolds and physiologic assessment of coronary arteries...
May 15, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28504230/macedonia-coronary-and-structural-heart-interventions-from-2010-to-2015
#5
Sasko Kedev, Biljana Zafirovska, Oliver Kalpak, Slobodan Antov, Jorgo Kostov, Igor Spiroski, Hristo Pejkov, Marjan Boshev, Ivan Vasllev, Aleksandar Jovkovski, Hajber Taravari, Danica Petkoska, Darko Kitanoski
The aim of this report is to describe invasive cardiology procedural practice in Macedonia during the period from 2010 to 2015. Details of all consecutive 39,899 patients who underwent cardiovascular, peripheral or structural heart procedures during the period from 2010 until 2015 were examined. Clinical and procedure characteristics, access site, procedural success and complications were analysed. The number of coronary angiographies increased from 5,540 in 2010 to 8,550 in 2015. Transfemoral access (TFA) was present in 4% of coronary angiographies in 2010 and had decreased to 1% in 2015...
May 15, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28504228/italy-coronary-and-structural-heart-interventions-from-2010-to-2015
#6
Sergio Berti, Ferdinando Varbella, Alfredo Marchese, Luigi Emilio Pastormerlo, Giuseppe Musumeci
The aim of this report is to analyse trends in Italian cathlab activity between 2010 and 2015. Data were obtained from the national database of the Italian Society of Interventional Cardiology (GISE), which includes 97% of Italian cardiac catheterisation laboratories. The number of percutaneous coronary interventions (PCI) has remained relatively stable in the past five years. We have observed a significant increase in the number of primary PCI (pPCI) from 471.5 to 557.5 per million inhabitants with a consequent reduction of rescue primary PCI/fibrinolysis...
May 15, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28504227/israel-coronary-and-structural-heart-interventions-from-2010-to-2015
#7
Ariel Finkelstein, Saar Minha, Ran Kornowski, Haim Danenberg, Shmuel Banai, Haim Lotan, Amit Segev, Israel M Barbash
The Israel Heart Society is a member of the European Society of Cardiology, and the Israeli Working Group of Interventional Cardiology is an active participant in EAPCI. The aim of this manuscript is to provide a snapshot of cardiac interventions performed in the State of Israel during the period 2010-2015. Data for this manuscript were collected via collaboration with the National Diseases Registries Unit of the Israel Center for Disease Control. During the survey period, the Israeli population increased by 7% but only one additional hospital with an active cardiac catheterisation laboratory was opened...
May 15, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28504225/egypt-coronary-and-structural-heart-interventions-from-2010-to-2015
#8
Ahmed Magdy, Ahmed Shawky, Ahmed Mohanad, Sameh Shaheen
Interventional cardiology procedures are constantly increasing in numbers and in quality, especially in developing countries such as Egypt. The numbers and types of procedure now available have driven development in the field and in its accompanying services. The aim of this short report is to present a review of the development of interventional cardiology in Egypt during the period 2010-2015 and the demographic, economic and educational factors that have affected this process. We collected and analysed data provided by different centres and from the distributors of intervention tools for the years 2010 to 2015...
May 15, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28504224/denmark-coronary-and-structural-heart-interventions-from-2010-to-2015
#9
Hans-Henrik Tilsted, Ole Ahlehoff, Christian J Terkelsen, Frants Pedersen, Cengiz Özcan, Troels H Jørgensen, Jens E Nielsen-Kudsk, Jan Ravkilde, Henrik Nissen, Sune A Pedersen, Ole Havndrup, Jens F Lassen
Interventional cardiology in Denmark has been carried out since the mid 1980s. Interventional cardiology is only performed at a few high-volume centres. Healthcare coverage is universal and is essentially free of charge. Hospitals are mostly publicly owned and financed by fixed budgets and, in part, an activity-based funding system. Approximately 30,000 coronary angiographies (CAG), 10,000 percutaneous coronary interventions (PCIs) of which approximately 25% are primary PCIs, and 500 transcatheter aortic valve implantations (TAVIs) are carried out each year...
May 15, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28502376/-2016%C3%A2-european-society-of-cardiology-guidelines-for-the-management-of-dyslipidemias
#10
Jean Ferrières
Cardiovascular risk evaluation is a fundamental approach in cardiovascular prevention. Cardiovascular risk categories are associated with lipid-lowering drug intensity. LDL cholesterol is the main target of treatment. Statins are the first line lipid-lowering drugs. Lipid-lowering combination therapy is to be used in order to obtain the LDL cholesterol targets. Screening of familial hypercholesterolemia might be included in all prevention population strategy.
May 10, 2017: La Presse Médicale
https://www.readbyqxmd.com/read/28497702/book-reviews-adverse-drug-interactions-a-handbook-for-prescribers-2nd-edn-edited-by-lakshman-delgoda-karalliedde-simon-fj-clarke-ursula-gotel-janaka-karalliedde-crc-press-2016-price-%C3%A2-44-99-pp-1089-isbn-9781482236217-orthogeriatrics-edited-by-paolo-falaschi
#11
https://www.readbyqxmd.com/read/28495431/evolution-of-australian-percutaneous-coronary-intervention-from-the-melbourne-interventional-group%C3%A2-mig-registry
#12
Julian Yeoh, Matias B Yudi, Nick Andrianopoulos, Bryan P Yan, David J Clark, Stephen J Duffy, Angela Brennan, Gishel New, Melanie Freeman, David Eccleston, Martin Sebastian, Christopher M Reid, William Wilson, Andrew E Ajani
Percutaneous coronary intervention (PCI) continues to evolve with shifting patient demographics, treatments, and outcomes. We sought to document the specific changes observed over a 9-year period in a contemporary Australian PCI cohort. The Melbourne Interventional Group is an established multicenter PCI registry in Melbourne, Australia. Data were collected prospectively with 30-day and 12-month follow-ups. Demographic, procedural, and outcome data for all consecutive patients were analyzed with a year-to-year comparison from 2005 to 2013...
April 12, 2017: American Journal of Cardiology
https://www.readbyqxmd.com/read/28492561/-sacubitril-valsartan-a-new-and-effective-treatment-for-heart-failure-with-reduced-ejection-fraction
#13
Michele Senni, Bruno Trimarco, Michele Emdin, Luciano De Biase
Despite significant therapeutic advances, patients with chronic heart failure and reduced ejection fraction (HFrEF) remain at high risk for heart failure progression and death. The PARADIGM-HF study, the largest outcome trial in HFrEF, has shown improved cardiovascular outcomes with sacubitril/valsartan (Entresto®, Novartis), previously known as LCZ696, compared with angiotensin-converting enzyme (ACE) inhibitor therapy, possibly leading us to a new era for heart failure treatment. Sacubitril/valsartan represents a first-in-class drug acting through inhibition of angiotensin receptor and neprilysin, thus modulating the renin-angiotensin-aldosterone system and vasoactive substances such as natriuretic peptides...
January 2017: Giornale Italiano di Cardiologia
https://www.readbyqxmd.com/read/28462716/treatment-of-bifurcation-lesions-by-bail-out-tap-or-culotte-lost-in-translation
#14
Francesco Burzotta, Thierry Lefèvre, Jens Flensted Lassen, Niels Ramsing Holm, Goran Stankovic
BACKGROUND: Coronary bifurcated lesions (CBL) represent a hot topic of interventional cardiology. Provisional stenting, i.e. implantation of a drug-eluting (DES) in the main branch followed by side-branch (SB) intervention in case of suboptimal SB result, represents the gold standard to treat the vast majority of CBL undergoing percutaneous coronary interventions (PCI). The best technique for bail-out SB stenting has not been established. Prospective randomized trials comparing different stenting techniques may help provide important insights regarding the best way to conduct PCI in patients with CBL...
April 26, 2017: Reviews on Recent Clinical Trials
https://www.readbyqxmd.com/read/28460763/a-clinical-evaluation-of-the-xience-v-everolimus-eluting-stent-in-the-treatment-of-patients-with-coronary-artery-disease-result-from-thailand-registry-xience-v-performance-evaluation-thrive-study
#15
Songsak Kiatchoosakun, Pavit Pienvichit, Srun Kuanprasert, Navin Suraphakdee, Arintaya Phromminikul
OBJECTIVE: To evaluate the 2-year clinical outcomes of XIENCE(TM) V everolimus eluting stent (EES) for the treatment of coronary artery disease. BACKGROUND: Percutaneous coronary intervention with a drug eluting stent has become the preferred treatment in patients with coronary artery disease. Everolimus eluting stent had proven efficacy in randomized control trials but those trials may not represent daily practice of interventional cardiology. METHODS: The THRIVE study was a prospective, multicenter, real-world, single-arm registry...
March 2017: Indian Heart Journal
https://www.readbyqxmd.com/read/28454812/factors-associated-with-rhythm-control-treatment-decisions-in-patients-with-atrial-fibrillation-insights-from-the-ncdr-pinnacle-registry
#16
Anil K Gehi, Gheorghe Doros, Thomas J Glorioso, Gary K Grunwald, Jonathan Hsu, Yang Song, Mintu P Turakhia, Alexander Turchin, Salim S Virani, Thomas M Maddox
BACKGROUND: Decisions to use rhythm control in atrial fibrillation (AF) should generally be dictated by patient factors, such as quality of life, heart failure, and other comorbidities. Whether or not other factors affect decisions about the use of rhythm control, and catheter ablation in particular, is unknown. METHODS: A cohort of all patients diagnosed with nonvalvular AF were identified from the National Cardiovascular Data Registry's Practice Innovation and Clinical Excellence (PINNACLE) AF registry of US outpatient cardiology practices during the study period from May 1, 2008, to December 31, 2014...
May 2017: American Heart Journal
https://www.readbyqxmd.com/read/28454799/long-term-electrocardiographic-safety-monitoring-in-clinical-drug-development-a-report-from-the-cardiac-safety-research-consortium
#17
REVIEW
Jonathan P Piccini, Richard L Clark, Peter R Kowey, Suneet Mittal, Preston Dunnmon, Norman Stockbridge, James A Reiffel, Mintu P Turakhia, Paul D Ziegler, Robert B Kleiman, Fraz Ismat, Philip Sager
This white paper, prepared by members of the Cardiac Safety Research Consortium (CSRC), discusses important issues regarding scientific and clinical aspects of long-term electrocardiographic safety monitoring during clinical drug development. To promote multistakeholder discussion of this topic, a Cardiac Safety Research Consortium-sponsored Think Tank was held on 2 December 2015 at the American College of Cardiology's Heart House in Washington, DC. The goal of the Think Tank was to explore how and under what circumstances new and evolving ambulatory monitoring technologies could be used to improve and streamline drug development...
May 2017: American Heart Journal
https://www.readbyqxmd.com/read/28440067/real-life-data-regard%C3%A4-ng-acute-procedural-success-and-1-year-clinical-outcome-of-desolve-bioresorbable-scaffolds
#18
Haci Murat Gunes, Tayyar Gokdeniz, Filiz Kizilirmak Yilmaz, Gultekin Gunhan Demir, Ekrem Guler, Gamze Babur Guler, Oğuz Karaca, Beytullah Cakal, Mehmet Onur Omaygenç, Ersin İbişoğlu, Bilal Boztosun
OBJECTIVES: We aimed to evaluate the peri-procedural success of DESolve bio-resorbable scaffolds (BRSs) and analyzed real-life data about major cardiac events during 1-year follow-up. BACKGROUND: There is little information about real-life data of DESolve BRS which is a novel stent technology offering various advantages over drug eluting stents and commonly used in daily cardiology practice. METHODS: We conducted this single-center and non-randomized cross-sectional study from June 2015 through August 2016 in Medipol University Department of Cardiology and included 117 patients undergoing single or multivessel percutaneous coronary interventions (PCI) with novolimus-eluting BRS devices (152 scaffolds) (Elixir Medical Corporation)...
April 25, 2017: Journal of Interventional Cardiology
https://www.readbyqxmd.com/read/28437620/american-association-of-clinical-endocrinologists-and-american-college-of-endocrinology-guidelines-for-management-of-dyslipidemia-and-prevention-of-cardiovascular-disease
#19
Paul S Jellinger, Yehuda Handelsman, Paul D Rosenblit, Zachary T Bloomgarden, Vivian A Fonseca, Alan J Garber, George Grunberger, Chris K Guerin, David S H Bell, Jeffrey I Mechanick, Rachel Pessah-Pollack, Kathleen Wyne, Donald Smith, Eliot A Brinton, Sergio Fazio, Michael Davidson
OBJECTIVE: The development of these guidelines is mandated by the American Association of Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology (ACE) Board of Trustees and adheres with published AACE protocols for the standardized production of clinical practice guidelines (CPGs). METHODS: Recommendations are based on diligent reviews of the clinical evidence with transparent incorporation of subjective factors, according to established AACE/ACE guidelines for guidelines protocols...
April 2017: Endocrine Practice
https://www.readbyqxmd.com/read/28434933/assessing-the-eligibility-criteria-in-phase-iii-randomized-controlled-trials-of-drug-therapy-in-heart-failure-with-preserved-ejection-fraction-the-critical-play-off-between-a-pure-patient-phenotype-and-the-generalizability-of-trial-findings
#20
Hitesh C Patel, Carl Hayward, Jason Dungu, Sofia Papadopoulou, Abdel Saidmeerasah, Carlo Di Mario, Nesan Shanmugam, Martin R Cowie, Lisa J Anderson
AIMS: To investigate the effect of the different eligibility criteria used by phase III clinical studies in heart failure with preserved ejection fraction (HFpEF) on patient selection, phenotype and survival. METHODS AND RESULTS: We applied the key eligibility criteria of seven phase III HFpEF studies (DIG-Ancillary, CHARM-Preserved, PEP-CHF, I-PRESERVE, J-DHF, TOPCAT and PARAGON-HF [on-going]) to a typical and well-characterised HFpEF population (n=557) seen in modern European cardiological practice...
April 18, 2017: Journal of Cardiac Failure
keyword
keyword
3059
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"